CytoDyn to Attend BIOCOM Global Life Sciences Partnering Conference
CytoDyn to Attend BIOCOM Global Life Sciences Partnering Conference
PORTLAND, Ore.--(BUSINESS WIRE)-- CytoDyn Inc. ("CytoDyn") (OTC QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that it will be presenting an update on the company's technology at the BIOCOM Global Life Sciences Partnering Conference at the Lodge in Torrey Pines, La Jolla, California.
"We are pleased to be included as a presenter in this select group of emerging biotechnology companies. BIOCOM provides us another excellent venue for CytoDyn to feature the company's exciting development initiatives such as PRO 140, our humanized monoclonal antibody for the treatment of HIV infection, and to update on the status of our other programs," said Dr. Nader Pourhassan, CytoDyn's CEO and President. "We are looking forward to the opportunity to present a concise and up-to-date review of the company's progress."
Dr. Richard Trauger, CytoDyn's Chief Scientific Officer, will present an overview of the company's programs on Wednesday, February 27 at 3:30 PM PT. The presentation will cover the status of PRO 140, an anti-CCR5 antibody experimental therapy for HIV infection, as well as a brief update on new preclinical findings demonstrating direct anti-viral activity of Cytolin, the company's early stage anti-CD11a antibody for the treatment of HIV.
CytoDyn is a biotechnology company focused on developing subcutaneously delivered humanized cell-specific monoclonal antibodies (mAbs) as entry inhibitors for the treatment and prevention of HIV and FIV. We currently have two mAbs under development for HIV infection. PRO 140, recently acquired from Progenics Pharmaceuticals, is a Late Stage II humanized mAb with demonstrated antiviral activity in man. PRO 140 blocks the Human Immunodeficiency Virus (HIV) co-receptor CCR5 without affecting the normal function of the molecule. Results from Phase I and Phase IIA human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. CytoDyn intends to continue to develop PRO 140 as a therapeutic anti-viral agent in persons infected with HIV. The second humanized mAb under development is Cytolin, which targets LFA-1, a membrane associated molecule reported to be important for entry and fusion of HIV to target cells and for cell-to-cell transmission. CytoDyn is also exploring the possibility that its anti-LFA-1 strategy to control HIV infection may be effective to treat feline immunodeficiency virus (FIV) a retroviral infection in cats, as well. To test this hypothesis, CytoDyn is developing CytoFeline, a monoclonal antibody that blocks feline LFA-1. For more information please go to www.cytodyn.com.
This press release includes forward-looking statements and forward-looking information within the meaning of United States securities laws. These statements and information represent CytoDyn's intentions, plans, expectations and beliefs, and are subject to risks, uncertainties and other factors, of which many are beyond CytoDyn's control. These factors could cause actual results to differ materially from such forward-looking statements or information. The words "believe," "estimate," "expect," "intend," "attempt," "anticipate," "foresee," "plan," and similar expressions and variations thereof, identify certain of such forward-looking statements or forward-looking information, which speak only as of the date on which they are made. CytoDyn disclaims any intention or obligation to publicly update or revise any forward-looking statements or forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Readers are cautioned not to place undue reliance on these forward-looking statements or forward-looking information.
While it is impossible to identify or predict all such matters, these differences may result from, among other things, the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and product candidates, including the risks that clinical trials will not commence or proceed as planned; products appearing promising in early trials will not demonstrate efficacy or safety in larger-scale trials; future clinical trial data on our products and product candidates will be unfavorable; our products will not receive marketing approval from regulators or, if approved, fail to gain sufficient market acceptance to justify development and commercialization costs; competing products currently on the market or in development may reduce the commercial potential of our products; CytoDyn, our collaborators or others may identify side effects after the product is on the market; or efficacy or safety concerns regarding marketed products, whether or not scientifically justified, may lead to product recalls, withdrawals of marketing approval, reformulation of the product, additional pre-clinical testing or clinical trials, changes in labeling of the product, the need for additional marketing applications, or other adverse events.
We are also subject to additional risks and uncertainties, including risks associated with the actions of our corporate, academic and other collaborators and government regulatory agencies; risks from market forces and trends; potential product liability; intellectual property, litigation, environmental and other risks; and risks that current and pending patent protection for our products may be invalid, unenforceable or challenged, or fail to provide adequate market exclusivity. There are also substantial risks arising out of our need to raise additional capital to develop our products and satisfy our financial obligations; the highly regulated nature of our business, including government cost-containment initiatives and restrictions on third-party payments for our products; the highly competitive nature of our industry; and other factors set forth in our Annual Report on Form 10-K and other reports filed with the U.S. Securities and Exchange Commission.
Media and IR Contact:
John Procter, 202-465-7786
KEYWORDS: United States North America California Oregon
The article CytoDyn to Attend BIOCOM Global Life Sciences Partnering Conference originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.